Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
217 hedge funds and large institutions have $2.25B invested in Sage Therapeutics in 2020 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 84 increasing their positions, 55 reducing their positions, and 57 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 55
42% more capital invested
Capital invested by funds: $1.59B → $2.25B (+$662M)
39% more call options, than puts
Call options by funds: $30.5M | Put options by funds: $21.9M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.26% less ownership
Funds ownership: 106.31% → 104.05% (-2.3%)
6% less funds holding
Funds holding: 230 → 217 (-13)
19% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$62M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$41.9M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$19.1M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$18.1M |
| 5 |
BlackRock
New York
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$118M |
| 2 |
Morgan Stanley
New York
|
-$30.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$28.7M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$22.7M |
| 5 |
Renaissance Technologies
New York
|
-$16.7M |
SAGE Hedge Fund Activity: Q2 2020 in Review
217 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2020, worth a combined $2.25B — up 42% from $1.59B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of SAGE and 46 opened new positions — a net loss of 11 holders — while 55 trimmed existing stakes and 84 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $62M. The largest seller was Capital International Investors, cutting an estimated $118M.
- 217 institutional investors held Sage Therapeutics (SAGE) as of Q2 2020, down from 230 in Q1 2020.
- Funds reported $2.25B of Sage Therapeutics stock for Q2 2020, up 42% quarter-over-quarter.
- 46 funds opened new Sage Therapeutics positions in Q2 2020 and 57 closed out, a net change of -11 holders.
- The largest Sage Therapeutics buyer in Q2 2020 was D.E. Shaw & Co, an estimated $62M added.
- The largest Sage Therapeutics seller in Q2 2020 was Capital International Investors, an estimated $118M sold.
Based on aggregated 13F filings for Q2 2020.